Document is current

Any future updates will be listed below

Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C

Crossref DOI link: https://doi.org/10.1007/s15010-016-0915-x

Published Online: 2016-06-16

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark